Researcher:
Akbaş, Sinem

Profile Picture
ORCID

Job Title

Doctor

First Name

Sinem

Last Name

Akbaş

Name

Name Variants

Akbaş, Sinem

Email Address

Birth Date

Filters

2021 - 20232

Advanced Search

Filter by

Settings

Researcher Of Publications: search.filters.isAuthorOfPublication.25356b1e-16d5-40db-8a12-c72aa5ab90b0

Search Results

Now showing 1 - 2 of 2
  • Placeholder
    PublicationMetadata only
    The roles of 68Ga-PSMA PET/CT and 18F-FDG PET/CT imaging in patients with triple-negative breast cancer and the association of tissue PSMA and claudin 1, 4, and 7 levels with PET findings
    (Springer, 2021) Arslan, E.; Ergul, N.; Beyhan, E.; Erol, O.; Cin, M.; Havare, S. Battal; Trabulus, D. Can; Mermut, O.; Cermik, T. F.; Akbaş, Sinem; Doctor; N/A; Koç University Hospital; N/A
    Aim of study is to compare the results of Gallium68-prostate-specific membrane antigen (68Ga-PSMA) and 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography(PET)/computed tomography (CT), to evaluate the correlation between PET findings and the level of PSMA, Claudin (Clau) 1, 4, and 7 receptors obtained by immunohistochemical (IHC) analysis, and to determine potential predictive and prognostic values in TNBC. Methods Forty-seven lesions of 42 subjects diagnosed TNBC both underwent PET/CT scan for preoperative staging/restaging were prospectively included study. PSMA, Clau 1, 4, and 7 expressions were IHC evaluated from the biopsy samples of the primary tumor (PT). Maximum standardized uptake value(SUV max) of the PT, lymph node, and distant organ metastases (DOMs) on 18F-FDG and 68Ga-PSMA PET/CT were compared with PSMA, Clau 1, 4, and 7 receptor expressions. Results IHC analyses on 29 BC lesions to demonstrate Clau expression showed 86% (25/29) Clau 1, 86% (25/29) Clau 4, 45% (13/29) Clau 7, and 48% (14/29) PSMA-positive. The mean DOM (SUVmax) was 15.5±11.6 for 18F-FDG and 6.0±2.9 for 68Ga-PSMA. Axial diameter of BC PT had a significant positive correlation with 18F-FDG SUVmax, 68Ga-PSMA SUVmax, and PSMA scores. BC lesions 68Ga-PSMA SUVmax had a significant negative correlation with the Ki-67 index. Axial diameter of the primary tumor had significant negative correlation with Clau 7 scores (r=−0.409, P=0.034). Absence of Clau 1 expression found to significantly increase the rate of DOM (100% vs. 28%) (P=0.014). All patients with axillary lymph node (ALN) metastases (n=17, 100%) exhibited Clau 4 positivity (P=0.021). The presence of PSMA expression observed to significantly increase the rate of ALN metastases (64.7% vs. 25%) (P=0.035). Conclusion Confirming PSMA expression with PET imaging would be significant as PSMA, a theranostic agent, may be a considerable potential agent for radionuclide treatment strategies, in addition to its additional diagnostic contribution to FDG, especially in patients with metastatic TNBC, which is an aggressive, heterogeneous disease.
  • Placeholder
    PublicationMetadata only
    The roles of Ga-68-PSMA PET/CT and F-18-FDG PET/CT imaging in patients with triple-negative breast cancer and the association of tissue PSMA and claudin 1, 4, and 7 levels with PET findings
    (Lippincott Williams and Wilkins (LWW), 2023) Arslan, Esra; Ergul, Nurhan; Beyhan, Ediz; Fenercioglu, Ozge Erol; Sahin, Rahime; Cin, Merve; Havare, Semiha Battal; Trabulus, Fadime Didem Can; Mermut, Ozlem; Cermik, Tevfik Fikret; N/A; Akbaş, Sinem; Doctor; N/A; Koç University Hospital; N/A
    Aim of study is to compare the results of Gallium-68-prostate-specific membrane antigen (Ga-68-PSMA) and F-18-fluorodeoxyglucose (F-18-FDG) positron emission tomography(PET)/computed tomography (CT), to evaluate the correlation between PET findings and the level of PSMA, Claudin (Clau) 1, 4, and 7 receptors obtained by immunohistochemical (IHC) analysis, and to determine potential predictive and prognostic values in TNBC. MethodsForty-seven lesions of 42 subjects diagnosed TNBC both underwent PET/CT scan for preoperative staging/restaging were prospectively included study. PSMA, Clau 1, 4, and 7 expressions were IHC evaluated from the biopsy samples of the primary tumor (PT). Maximum standardized uptake value(SUV max) of the PT, lymph node, and distant organ metastases (DOMs) on F-18-FDG and Ga-68-PSMA PET/CT were compared with PSMA, Clau 1, 4, and 7 receptor expressions. ResultsIHC analyses on 29 BC lesions to demonstrate Clau expression showed 86% (25/29) Clau 1, 86% (25/29) Clau 4, 45% (13/29) Clau 7, and 48% (14/29) PSMA-positive. The mean DOM (SUVmax) was 15.5 +/- 11.6 for F-18-FDG and 6.0 +/- 2.9 for Ga-68-PSMA. Axial diameter of BC PT had a significant positive correlation with F-18-FDG SUVmax, Ga-68-PSMA SUVmax, and PSMA scores. BC lesions Ga-68-PSMA SUVmax had a significant negative correlation with the Ki-67 index. Axial diameter of the primary tumor had significant negative correlation with Clau 7 scores (r = -0.409, P = 0.034). Absence of Clau 1 expression found to significantly increase the rate of DOM (100% vs. 28%) (P = 0.014). All patients with axillary lymph node (ALN) metastases (n = 17, 100%) exhibited Clau 4 positivity (P = 0.021). The presence of PSMA expression observed to significantly increase the rate of ALN metastases (64.7% vs. 25%) (P = 0.035). ConclusionConfirming PSMA expression with PET imaging would be significant as PSMA, a theranostic agent, may be a considerable potential agent for radionuclide treatment strategies, in addition to its additional diagnostic contribution to FDG, especially in patients with metastatic TNBC, which is an aggressive, heterogeneous disease.